Evidence map›Paper›PMID 41444295›Full record

ArticleScientific reports2025

The extent of alpha-synuclein aggregate accumulation in neurons varies depending on the type of neurotransmitter they release.

Hiroshi Kameda, Shinichiro Okamoto, Kakeru Ogasawara, Ayami Okuzumi, Nobutaka Hattori, Hiroyuki Hioki, Masato Koike

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hiroshi KamedaDepartment of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
Shinichiro OkamotoDepartment of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kakeru OgasawaraDepartment of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
Ayami OkuzumiDepartment of Neurology, Juntendo University School of Medicine, Bunkyo- ku, Tokyo, 113-8421, Japan.
Nobutaka HattoriDepartment of Neurology, Juntendo University School of Medicine, Bunkyo- ku, Tokyo, 113-8421, Japan.
Hiroyuki HiokiDepartment of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
Masato KoikeDepartment of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan. mkoike@juntendo.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-synuclein (aSyn) is a highly conserved 140-amino acid presynaptic protein involved in neuronal plasticity and recognized as the pathogenic protein in Parkinson's disease. Aggregated aSyn propagates transsynaptically between neurons in vivo, impairing the cellular function of affected cells. However, it remains unclear whether aggregated aSyn propagates similarly across all neuronal cell types. In this study, we injected sonicated aSyn preformed fibrils into the striatum of mice and used immunohistochemistry to observe the intracellular localization of aSyn aggregates at designated survival times. Four weeks post-injection, numerous filamentous aggregates were detected in the striatum, neocortex, and substantia nigra. Multiple immunostaining techniques with neuronal markers, combined with electron microscopy, revealed that some filamentous aggregates accumulated in the perinuclear cytoplasm of neurons in these regions. However, quantitative analyses revealed that the number of cell bodies containing aSyn aggregates in the striatum was significantly lower than that in the neocortex or substantia nigra. Additionally, we examined aSyn aggregates in the glial cells of the striatum and found that filamentous aggregates were rarely detected, even 16 weeks post-injection. These findings suggest a cell-type preference depending on neurotransmitter identity for aSyn aggregation and propagation in vivo.

Indexed as

alpha-SynucleinNeuronsNeurotransmitter AgentsProtein AggregatesProtein Aggregation, PathologicalAnimalsCorpus StriatumMaleMiceMice, Inbred C57BLNeocortexParkinson DiseaseSubstantia Nigraalpha-SynucleinNeurotransmitter AgentsProtein AggregatesAlpha-synucleinMouse modelsNeurodegenerationNeuronal cell typesParkinson’s diseaseProtein aggregation

Identifiers

PMID41444295
PMCPMC12738881

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.